Biomarin (BMRN) Fundamental Analysis: Revenue, Earnings & Valuation

4.68 / 10

Netural

Fundamental health scores 4.7/10, with solid inventory turnover, fixed‑asset turnover, cost‑of‑sales ratio and interest coverage. Weakness lies in accounts‑receivable turnover. Overall balance is moderate, indicating neither strong growth nor severe risk.

Analysis Checks(9/10)

Revenue-MV

Value-0.25

Score3/3

Weight28.60%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value12.87

Score2/3

Weight1.52%

1M Return0.58%

Inventory turnover ratio

Value0.57

Score2/3

Weight-1.80%

1M Return-0.66%

Accounts receivable turnover ratio

Value4.11

Score1/3

Weight-4.05%

1M Return-1.57%

PB-ROE

Value0.44

Score2/3

Weight32.07%

1M Return8.98%

Income tax / Total profit (%)

Value27.69

Score2/3

Weight9.90%

1M Return3.20%

Fixed assets turnover ratio

Value3.23

Score2/3

Weight-2.57%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-1.81%

1M Return-0.73%

Cost of sales ratio (%)

Value22.27

Score3/3

Weight2.26%

1M Return0.79%

Asset-MV

Value-0.55

Score2/3

Weight35.88%

1M Return9.91%

Is BMRN fundamentally strong?

BMRN scores 4.68/10 on fundamentals and holds a Fair valuation at present. Backed by its 5.94% ROE, 10.83% net margin, 30.64 P/E ratio, 1.76 P/B ratio, and -19.11% earnings growth, these metrics solidify its Netural investment rating.